{"id":10174,"date":"2026-05-27T06:33:49","date_gmt":"2026-05-27T11:33:49","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10174"},"modified":"2026-05-27T06:38:04","modified_gmt":"2026-05-27T11:38:04","slug":"nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/","title":{"rendered":"Nanoscope Therapeutics selecciona a InspiroGene de McKesson para respaldar la distribuci\u00f3n de una nueva terapia retiniana."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a0<\/strong>27 de mayo,<\/strong> 2026 <\/strong><\/span>\u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, InspiroGene, una empresa de biotecnolog\u00eda centrada en el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que ha seleccionado a InspiroGene by McKesson para que le preste servicios de comercializaci\u00f3n en EE. UU. para su producto principal, MOGENRY\u2122, sujeto a la aprobaci\u00f3n regulatoria de EE. UU.<\/p>

InspiroGene will support the U.S. distribution of Nanoscope’s anticipated retinal therapy through its specialty pharmacy, specialty distribution, and patient hub services. The collaboration is focused on US commercialization and supply chain services to provide a best-in-class experience for patients and providers as Nanoscope launches the first optogenetic gene therapy for the US market.\u00a0<\/p>

“Nanoscope is advancing extraordinary science with a clear commitment to improving patients’ lives,” said Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. “InspiroGene by McKesson is proud to help advance these therapies while supporting patients and providers as they navigate the value chain and access these important innovations.”<\/p>

Nanoscope’s clinical programs target patients with retinal degenerative diseases, including retinitis pigmentosa, addressing a significant unmet medical need. The company’s approach is designed for use without a surgical implant or light-intensifying device, simplifying treatment logistics within specialty care settings.<\/p>

“Engaging with InspiroGene is an important step in our commercialization readiness planning,” said Sulagna Bhattacharya, CEO of Nanoscope Therapeutics. “InspiroGene’s experience in full-service patient support and its expertise across the U.S. healthcare system position them well to support efficient product delivery following regulatory approval.”<\/p>

El acuerdo tiene como objetivo respaldar la preparaci\u00f3n para el lanzamiento, la gesti\u00f3n de inventario, el cumplimiento de pedidos y el cumplimiento de los requisitos reglamentarios y de calidad aplicables.<\/p>

Acerca de la plataforma MCO<\/b><\/p>

MCO es una plataforma terap\u00e9utica experimental, de una sola aplicaci\u00f3n, intrav\u00edtrea y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual existente tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que reduce la carga del tratamiento para el paciente y permite una amplia aplicabilidad dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics<\/b><\/p>

Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, as\u00ed como las designaciones Sakigake y hu\u00e9rfana de la PMDA para distrofias retinianas hereditarias (IRD) y las designaciones hu\u00e9rfana de la EMA y la SFDA para IRD. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Nanoscope Therapeutics, Inc.
+1 (817) 857-1186
PR@nanostherapeutics.com<\/a>\u00a0<\/p>

FUENTE Nanoscope Therapeutic<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0May 27, 2026 —\u00a0Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease\u2011agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product, MOGENRY\u2122, subject to U.S. regulatory approval. InspiroGene will […]<\/p>\n","protected":false},"author":1,"featured_media":10175,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T11:33:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T11:38:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy\",\"datePublished\":\"2026-05-27T11:33:49+00:00\",\"dateModified\":\"2026-05-27T11:38:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/\"},\"wordCount\":541,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_INSPIROGENE_Patient.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/\",\"name\":\"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_INSPIROGENE_Patient.jpg\",\"datePublished\":\"2026-05-27T11:33:49+00:00\",\"dateModified\":\"2026-05-27T11:38:04+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_INSPIROGENE_Patient.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_INSPIROGENE_Patient.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/27\\\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics selecciona a InspiroGene de McKesson para respaldar la distribuci\u00f3n de una nueva terapia retiniana - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-05-27T11:33:49+00:00","article_modified_time":"2026-05-27T11:38:04+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy","datePublished":"2026-05-27T11:33:49+00:00","dateModified":"2026-05-27T11:38:04+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/"},"wordCount":541,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_INSPIROGENE_Patient.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/","url":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/","name":"Nanoscope Therapeutics selecciona a InspiroGene de McKesson para respaldar la distribuci\u00f3n de una nueva terapia retiniana - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_INSPIROGENE_Patient.jpg","datePublished":"2026-05-27T11:33:49+00:00","dateModified":"2026-05-27T11:38:04+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_INSPIROGENE_Patient.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_INSPIROGENE_Patient.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/27\/nanoscope-therapeutics-selects-inspirogene-by-mckesson-to-support-distribution-of-novel-retinal-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10174"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10174\/revisions"}],"predecessor-version":[{"id":10179,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10174\/revisions\/10179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10175"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}